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Background: S-1, a novel oral ﬂuoropyrimidine, is well tolerated in patients with metastatic colorectal cancer
(mCRC). The response rate of S-1 for colorectal cancer is high, ranging from 35% to 40%. This study aimed to
evaluate the safety and efﬁcacy of S-1 combined with oral leucovorin (LV) to enhance antitumor activity in
chemotherapy-naive patients with mCRC.
Patients and methods: S-1 was given orally twice daily for two consecutive weeks at a daily dose of 80–120 mg,
followed by a 2-week rest period, within a 4-week cycle. LV was given orally twice a day at a daily dose of 50 mg,
simultaneously with S-1.
Results: Of the 56 patients with previously untreated mCRC, 32 (57%) had partial responses. The median follow-up
period was 27.2 months. The median time to progression was 6.7 months (95% conﬁdence interval 5.4–7.9). The
median survival time was 24.3 months. There was no treatment-related death or grade 4 toxicity. The most common
grade 3 toxic effects were diarrhea (32%), anorexia (21%), stomatitis (20%), and neutropenia (14%).
Conclusion: S-1 combined with LV therapy demonstrated promising efﬁcacy and acceptable safety in
chemotherapy-naive patients with mCRC without the concurrent use of irinotecan, oxaliplatin, or molecular-targeted
drugs.
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introduction
Recently, the development of irinotecan and oxaliplatin in
combination with 5-ﬂuorouracil (5-FU)-based regimens has
led to signiﬁcant improvement of survival in patients with
metastatic colorectal cancer (mCRC). Various phase III studies
of ﬁrst-line chemotherapy have reported combination therapy
with i.v. 5-FU/leucovorin (5-FU/LV) plus oxaliplatin (FOLFOX
regimen) or 5-FU/LV plus irinotecan (FOLFIRI regimen) as
a standard regimen for mCRC [1–4]. Recent clinical trials have
examined whether oral ﬂuoropyrimidines such as uracil–
tegafur (UFT)/LV and capecitabine could be a replacement for
i.v. 5-FU/LV. A combination of capecitabine and oxaliplatin
(XELOX regimen) was found not to be inferior to FOLFOX in
terms of progression-free survival (PFS) [5]. The standard
treatment of mCRC is consequently shifting from 5-FU/LV-
based regimens, which require central venous access, to more
convenient oral-based care.
S-1 is a capsule preparation combining FT, an oral 5-FU
derivative, with gimeracil (CDHP) and oteracil potassium
(Oxo) at a molar ratio of 1.0 : 0.4 : 1.0. CDHP reversibly
inhibits the activity of dihydropyrimidine dehydrogenase
(DPD), a metabolizing enzyme of 5-FU. Oxo inhibits the
activity of orotate phosphoribosyltransferase and is distributed
in high concentrations in the gastrointestinal (GI) tract,
where it suppresses GI disorders caused by 5-FU.
In Japan, S-1 was approved for the treatment of gastric
cancer in 1999 and was subsequently approved for the
treatment of colorectal cancer (CRC), head and neck cancer,
non-small-cell lung cancer, inoperable or recurrent breast
cancer, pancreatic cancer, and biliary tract cancer. Recently,
several phase III studies have established S-1 as a standard
treatment of gastric cancer, including postoperative adjuvant
chemotherapy [6–8]. Two phase II studies of S-1 were
conducted in patients with mCRC. Single-agent S-1 was shown
to be very effective, with high response rates (36% and 40%)
and good median survival times (MSTs) (12 months) for at
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second-line therapies available [9, 10].
LV is known to enhance the efﬁcacy of 5-FU by inhibiting
thymidylate synthase. A meta-analysis consisting of >3000
patients’ clinical data revealed that LV improves response rates
and overall survival (OS) when combined with 5-FU, as
compared with 5-FU alone [11]. Oral UFT/LV has been shown
to be as effective as i.v. 5-FU/LV (Mayo regimen), with
signiﬁcantly favorable safety proﬁle against metastatic disease
[12, 13]. In an adjuvant setting, oral UFT/LV regimen was
demonstrated to be as effective as i.v. 5-FU/LV (Roswell Park
Memorial Institute regimen) in patients with curatively
resected stage II/III colon cancer [14]. On the other hand,
addition of oral LV to another ﬂuoropyrimidine, capecitabine,
leads to increased GI toxicity or hand–foot skin reaction,
with no enhancement of response [15].
In a phase I study of oral LV plus S-1 in patients with mCRC,
recommended treatment schedule with ﬁxed dose of S-1 and
LV was determined. S-1 and LV were administered twice a day
at a daily dose of 80–120 mg for S-1, a conventional dose of S-1,
and 25 mg for LV. The dose (schedule)-limiting toxic effects
(DLTs) were mainly GI symptoms such as grade 3 stomatitis/
pharyngitis, nausea, diarrhea or ileus, and exanthema. The
response rate was 67% (10 of 15). The recommended treatment
schedule was 2 weeks of administration followed by 2 weeks
of rest [16]. To evaluate the safety and efﬁcacy of
a combination of S-1 and LV (S-1/LV regimen) given in the
recommended schedule, we conducted a phase II study in
chemotherapy-naı ¨ve patients with mCRC.
patients and methods
patient selection
Eligible patients had histologically conﬁrmed CRC; have at least one
measurable lesion; adequate oral intake; aged 20–74; no previous treatment
of metastatic disease (adjuvant chemotherapy was allowed if ﬁnished
180 days before enrollment); an Eastern Cooperative Oncology Group
performance status of zero to two; adequate bone marrow, liver, and renal
functions as follows: a serum hemoglobin concentration of ‡9.0 g/dl,
a white blood cell count of 4000–12 000/mm
3, a neutrophil count of ‡2000/
mm
3, a platelet count of ‡100 000/mm
3, a serum total bilirubin
concentration of £1.5 mg/dl, serum aspartate aminotransferase and alanine
aminotransferase concentrations of £100 IU/l, a serum alkaline phosphatase
level of less than twice the upper limit of the normal institutional level
(ULN), and a serum creatinine level of less than ULN; and written informed
consent. Patients were excluded from this study if they had
a contraindication for S-1; a history of serious hypersensitivity to LV; an
active infection; serious concomitant diseases or conditions (intestinal
obstruction, pulmonary ﬁbrosis, heart failure, renal failure, liver failure,
etc.); severe ascites or pleural effusion; extensive bone metastasis; brain
metastasis or symptoms of brain metastasis; diarrhea (watery stools); or
another synchronous cancer. We also excluded patients participating in
other clinical studies; women who were pregnant, nursing infants, possibly
pregnant, or planning to become pregnant; and men who were intending to
conceive children.
treatment plan
S-1 (capsules containing 20 or 25 mg of FT) and LV (25-mg tablets)
were provided by Taiho Pharmaceutical Co., Ltd, Tokyo, Japan. The dose
of S-1 was determined according to body surface area as follows: <1.25 m
2,
40 mg; 1.25–1.50 m
2, 50 mg; and ‡1.50 m
2, 60 mg. LV was given at a ﬁxed
dose of 25 mg each time. S-1 and LV were given together orally twice a day
for two consecutive weeks, followed by 2 weeks rest. This 4-week cycle was
repeated until the onset of disease progression or unacceptable adverse
events. No pretreatment was allowed. The dose of S-1 could be decreased by
one level in the event of the following toxicity: grade 4 leucopaenia or
thrombocytopaenia; grade 4 non-hematologic toxicity; or grade 3 diarrhea,
stomatitis, skin conditions, or febrile neutropaenia that did not resolve with
symptomatic treatment. The dose of LV could not be decreased.
toxicity and response criteria
Laboratory and clinical examinations were carried out within 15 days before
enrollment, every 1 week during the ﬁrst course of treatment and every
2 weeks from the second course onward. Tumors were evaluated on the
basis of computed tomographic scans and serum carcinoembryonic antigen
levels within 30 days before enrollment and every 4–6 weeks after the start
of treatment. In the assessment of the best overall response, a complete
response (CR: the disappearance of all lesions and normalization of tumor
marker level) or partial response (PR: at least a 30% decrease in the sum of
the longest diameter of all measured lesions taking as reference the baseline
sum longest diameter) had to continue for at least 4 weeks and to be
conﬁrmed. A best overall response of stable disease (SD: neither sufﬁcient
shrinkage to quality for PR nor sufﬁcient increase to qualify for PD taking
as reference the smallest sum longest diameter since the treatment started)
required no evidence of progressive disease (PD: at least a 20% increase in
the sum of the longest diameter of all measured lesions taking as reference
the smallest sum longest diameter recorded since the treatment started or
the appearence of new lesion) for at least 6 weeks after the start of
treatment. Response to S-1/LV treatment was externally reviewed and
analyzed. Tumors were assessed according to RECIST criteria. Toxicity was
evaluated according to the Common Terminology Criteria for Adverse
Events (version 3.0).
statistical analysis
The response rate in previous phase II studies of S-1 alone in patients with
CRC was 33% [42 of 129; 95% conﬁdence interval (CI) 25–41]. Therefore,
the threshold rate of response to the S-1/LV regimen was set at 30%, and
the expected response rate was estimated to be 50%, which was 20
percentage points higher than the response rate for S-1 alone. Assuming
that the response rate follows a binomial distribution, we calculated the
number of patients required to obtain the expected response rate (given
a threshold response rate of 30%), with a one-sided test, a signiﬁcance level
of 2.5% (a/2 = 2.5%), and a statistical power (1-b) of 80%. We estimated
that a target sample size of 54 patients would be needed to reject the null
hypothesis with a power of 80%.
The Kaplan–Meier method was used to estimate time to progression
(TTP), time to treatment failure (TTF), and OS. All data obtained until the
completion of the study period were included in the safety analyses. Clinical
cut-off date for this study was 25 June 2008.
The study was approved by the institutional review board at each
participating center. For the duration of the study, an independent
data-monitoring committee monitored safety. The study was undertaken
in accordance with the Helsinki Declaration and Japanese Good Clinical
Practice Guidelines.
results
patient characteristics
From October 2005 through June 2006, a total of 56 patients
were enrolled from 12 hospitals: all were eligible. Patient
characteristics are described in Table 1. A total of 406 courses of
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median number of treatment courses was 6 (range 1–26). The
median treatment period was 5.1 months (range 0.3–29.4). The
median relative dose intensity was 81% (range 43–109) for S-1
and 93% (range 49–113) for LV.
response to therapy
The response rate, which was the primary end point of this
study, was evaluated in all 56 patients. No patient had
a complete response, but 32 had PRs, 16 had stable disease,
and 8 had progressive disease. The response rate was 57%
(95% CI 43–70) (Table 2). The median time to response was
1.9 months (range 0.9–5.3).
With a median follow-up time of 27.2 months, the median
TTP was 6.7 months (95% CI 5.4–7.9) (Figure 1). The
median TTF was 6.0 months (95% CI 5.4–7.8). The MST was
24.3 months (95% CI 17.5–XXX; upper bound of 95% CI
was not estimable) (Figure 2) with the survival rate of 86% at
1 year and 52% at 2 years. Second-line treatment, including
curative or palliative surgery, was given to 52 (93%) of the
56 patients, among whom 36% received oxaliplatin-based
chemotherapy and 41% received irinotecan-based
chemotherapy (Table 3).
Table 1. Patient characteristics
Characteristics N = 56
n %
Gender
Male 30 54
Female 26 46
Age, years
Median 62
Range 32–72
ECOG performance status
05 3 9 5
13 5
20 0
Primary site
Colon 32 57
Rectum 24 43
Histologic grading
Well differentiated 20 36
Moderately differentiated 29 52
Poorly differentiated 5 9
Mucinous 2 4
Site of metastases
Liver 39 70
Lung 26 46
Lymph nodes 24 43
Peritoneum 3 5
Other 7 13
No. of sites evaluated
12 4 4 3
22 0 3 6
38 1 4
42 4
‡52 4
Prior adjuvant therapy
Yes 10 18
No 46 82
Hemoglobin (g/dl)
Median 12.50
Range 9.0–16.8
Alkaline phosphatase (IU/l)
Median 280.0
Range 137–1408
ECOG, Eastern Cooperative Oncology Group.
Table 2. Tumor response
N = 56
n %
Complete response 0 0
Partial response 32 57
Stable disease 16 29
Progressive disease 8 14
Not evaluable 0 0
Overall response rate (%) 32 57
95% CI 43.2–70.3
Time to progression, months
Median 6.7
95% CI 5.4–7.9
Tumor response was externally assessed according to the RECIST criteria.
CI, conﬁdence interval.
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Figure 1. Kaplan–Meier curve of time to progression.
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Figure 2. Kaplan–Meier curve of overall survival.
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The most frequent common adverse events are shown in
Table 2. Grade 3 toxicity occurred in 35 patients (55%).
There was no grade 4 toxicity. Grade 3 toxic effects with an
incidence of ‡10% were given to diarrhea (32%), anorexia
(21%), stomatitis (20%), and neutropaenia (14%) (Table 4).
The dose had to be decreased at least once in 33 patients
(59%). The median number of treatment courses until the dose
of S-1 was initially decreased was 2 (range 1–4). The main
reasons for dose reductions were diarrhea, stomatitis, and rash.
Rest periods were prolonged in 53.6% of the patients, mainly
because of diarrhea, stomatitis, and rash, similar to the
reasons for dose reductions.
The median times to the onset of diarrhea, stomatitis, and
rash were 15 days (range 1–169), 12 days (range 3–201), and
8 days (range 3–148), respectively. The median times to the
worst grade of these toxic effects were 20 days (range 1–769),
14 days (range 5–237), and 10 days (range 3–148), respectively.
The median times from the worst grade to the resolution of
these toxic effects were 7 days (range 1–29), 10 days (range
2–79), and 10 days (range 1–70), respectively.
The reasons for the withdrawal of treatment were mainly
disease progression (86%). Withdrawal due to toxic effects was
rare (4%) and there were no treatment-related deaths.
discussion
This phase II trial was conducted to evaluate the response rate
of the S-1/LV regimen in patients with previously untreated
mCRC. All 56 enrolled patients were eligible. S-1/LV regimen
yielded promising results, without combination with
oxaliplatin, irinotecan, or molecular-target agent as ﬁrst-line
treatment. The response rate, the primary end point of this
trial, was 57%. With a median follow-up time of 27.2 months,
the median TTP was 6.7 months, the MST was 24.3 months,
and survival rates were 86% at 1 year and 52% at 2 years. In
previous phase II studies of single-agent S-1, the response rate
was 35%–40%, the median TTP was 5.3 months, and the MST
was 12 months. In these studies, S-1 was given for 4 weeks,
followed by 2 weeks of rest [9, 10]. In our study, the S-1
combined with LV was clearly more effective than S-1 alone,
despite a shorter treatment period (2 versus 4 weeks). The
antitumor activity of 5-FU is thought to involve the following
mechanism: 5-ﬂuoro-2#-deoxyuridine-5#-monophosphate,
a metabolite of 5-FU, forms a ternary complex with
thymidylate synthase and 5,10-methylenete terahydrofolate,
a metabolite of LV. This complex inhibits thymidylate synthase,
thereby blocking DNA synthesis [17]. In our study,
enhancement of the antitumor activity of S-1 by oral LV is
ascribed to this mechanism.
UFT is a derivative of 5-FU which is the same as S-1 and is
a compounding oral agent of FT and uracil. In vitro, CDHP
has been shown to inhibit DPD activity 180-fold higher than
uracil [18]. In the previous pharmacokinetic (PK) studies, there
was difference in PK proﬁle about 5-FU between S-1 and UFT.
Compared with UFT, S-1 showed longer maximum plasma
concentration time (Tmax) (3.5 versus 1.1 h), lower maximum
plasma concentration (Cmax) (128.5 versus 265 ng/ml) and
longer half-time (T1/2) (1.9 versus 0.34 h). The area under the
curve (AUC) of 5-FU were 723.9 ngh/ml for S-1 (AUC0–14 h)
and 338 ngh/ml for UFT (AUC0–8 h) [19, 20]. In this study,
S-1/LV regimen demonstrated higher response rate and longer
TTP compared with previously reported UFT/LV [12, 13].
Although these comparisons are limited in value, it was
considered that these differences were due to the difference in
the inhibitory effect of DPD.
In phase III studies of 5-FU/LV reported in the past decade
or so, response rates were 10%–30%, with a PFS/TTP of
4.5–6.0 months. Response rates with FOLFOX or FOLFIRI
range from 30% to 55%, with a PFS/TTP of 7.0–8.5 months
[21, 22]. XELOX regimen showed response rates of 48% and
a PFS of 7.1 months [23]. Although there is limitation to
Table 3. Further treatment after study chemotherapy
N = 56
n %
Oxaliplatin based 20 36
Irinotecan based 23 41
Surgery
Curative 3 5
Palliative 2 4
None 4 7
Other 4 7
Table 4. Hematological and non-hematological adverse events
N = 56
All
grade (%)
Grade
3 (%)
Grade
4 (%)
Leucopaenia 31 (55) 0 0
Neutropaenia 36 (64) 8 (14) 0
Anemia 35 (63) 2 (4) 0
Thrombocytopaenia 14 (25) 1 (2) 0
AST 17 (30) 0 0
ALT 20 (36) 1 (2) 0
Bilirubinaemia 25 (45) 1 (2) 0
Nausea 42 (75) 1 (2) 0
Vomiting 20 (36) 1 (2) 0
Stomatitis 49 (88) 11 (20) 0
Abdominal pain 18 (32) 0 0
Diarrhea 46 (82) 18 (32) 0
Fatigue 48 (86) 0 0
Anorexia 48 (86) 12 (21) 0
Weight loss 21 (38) 1 (2) 0
Rash 33 (59) 1 (2) 0
Skin exfoliation 21 (38) 0 0
Hand–foot syndrome 4 (7) 0 0
Pigmentation disorder 50 (89) 0 0
Lacrimation increased 18 (32) 1 (2) 0
Dysgeusia 31 (55) 0 0
Numbers are patients who reported events. Severity was graded according
to the CTCAE, version 3.0.
AST, aspartate aminotransferase; ALT, alanine aminotransferase; CTCAE,
Common Terminology Criteria for Adverse Events.
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this study (Asians) and referred studies (Western countries),
the S-1/LV regimen has one of the highest response rates,
despite the absence of oxaliplatin and irinotecan, among
currently available regimens not including molecular-targeted
drugs such as bevacizumab. The efﬁcacy proﬁles of S-1 seemed
to be generally better in Asian studies than that of others;
however, it remained still unclear whether this difference was
due to ethnic difference or good selected study population.
Recent clinical trials in patients with mCRC have not only
compared treatment regimens but also examined strategies for
subsequent treatment. The capecitabine, irinotecan, and
oxaliplatin (CAIRO) trial compared sequential chemotherapy
(ﬁrst-line capecitabine, second-line irinotecan, and third-line
capecitabine plus oxaliplatin) with combination chemotherapy
(ﬁrst-line capecitabine plus irinotecan and second-line
capecitabine plus oxaliplatin). OS did not differ signiﬁcantly
between sequential chemotherapy and combination
chemotherapy [hazard ratio (HR) = 0.92; 95% CI 0.79–1.08;
P = 0.33 by the log-rank test]. Sequential therapy was thus
considered a valid treatment option for mCRC [24]. The 5-FU,
oxaliplatin, and irinotecan: use and sequencing (FOCUS) trial,
compared three different strategies of sequential and
combination chemotherapy in patients with unresectable
mCRC: single-agent 5-FU (given with levofolinate), followed by
single-agent irinotecan (strategy A, control group); 5-FU,
followed by combination chemotherapy (strategy B); and
combination chemotherapy from the outset (strategy C).
Compared with strategy A, strategy B did not signiﬁcantly
prolong survival (HR = 0.94; 95% CI 0.84–1.05; P = 0.24 by
the log-rank test), whereas strategy C did (HR = 0.88; 95% CI
0.79–0.98, P = 0.02 by the log-rank test). There was no
signiﬁcant difference in survival between strategy B and strategy
C (HR = 1.06; 90% CI 0.97–1.17). The FOCUS trial concluded
that maximum tolerable treatment should be used as ﬁrst line
in the noncurative setting, and the staged approach of initial
single-agent treatment upgraded to combination was not
inferior to ﬁrst-line combination therapy. This was an
alternative option for discussion with patients [25]. At present,
sequential therapy is recognized as a useful alternative for
combined therapy.
After the study treatment, 93% of the patients in our study
were given subsequent therapy. Of the 56 patients, 36%
received oxaliplatin-based chemotherapy, 41% received
irinotecan-based chemotherapy, and 5% underwent curative
surgery. At the time of starting this trial, neither the FOLFOX
nor the FOLFIRI regimen and no bevacizumab was approved in
Japan. Grothey et al. [26] found that 5-FU, oxaliplatin, and
irinotecan contributed to prolonged survival. In fact,
Tournigand et al. [21] reported that survival exceeded
20 months in patients with mCRC who were enrolled in
a crossover study of FOLFOX and FOLFIRI. The good survival
in our study seems to be attributed to three reasons. First, the
relatively recent approval of the FOLFOX and FOLFIRI
regimens for use in Japan increased options for subsequent
treatment. Secondly, the S-1/LV regimen, an intensive
treatment that does not include oxaliplatin or irinotecan, was
given as ﬁrst-line therapy. Thirdly, the S-1/LV regimen was
associated with a low rate of treatment withdrawal due to
toxicity and a high rate of subsequent therapy; consequently,
a high proportion of patients were able to receive sequential
chemotherapy.
As for safety, there was no grade 4 toxicity or treatment-
related mortality in our study. Common non-hematologic toxic
effects included pigmentation, stomatitis, anorexia, fatigue,
diarrhea, nausea, rash, and taste disorders. The incidences of
grade 3 diarrhea, anorexia, and stomatitis were 32%, 21%, and
20%, respectively. Although these rates are higher than those
reported for single-agent S-1 or standard chemotherapy, these
toxic effects did not raise treatment discontinuation. The
median number of courses until the ﬁrst decrease in the dose of
S-1 was 2 (range 1–4). The dose was decreased in 33 patients
(59%). The main reasons for decreases in dose were stomatitis
(11 patients), diarrhea (11 patients), and rash (nine patients).
Mucositis characterized by stomatitis and diarrhea was
considered the DLT of the S-1/LV regimen. Observed DLT was
shifted from hematological toxicity to GI toxicity when S-1
was administered with LV. The median time to the onset of
the worst grade of diarrhea and stomatitis was 14–20 days after
the start of treatment. These toxic effects resolved after
7–10 days. Our experience indicates that toxicity associated
with the S-1/LV regimen is manageable by appropriately
reducing the dose of S-1 or by extending the rest period
between treatment courses. So the S-1/LV regimen was
generally well tolerated, with an acceptable toxicity proﬁle.
Both S-1 and LV are administered orally, so this regimen
does not require a central venous port. Patients therefore have
to spend less time on follow-up visits, and the convenience
of oral administration makes the S-1/LV regimen extremely
useful clinically. Another advantage is the low incidence of
hand–foot syndrome, the most common toxicity of
capecitabine, another oral ﬂuoropyrimidine.
In phase I/II studies of S-1 combined with oxaliplatin (SOX
regimen), S-1 was given for 2 weeks at the conventional dose in
Japan, similar to our S-1/LV regimen, followed by 1 week of
rest. Oxaliplatin (130 mg/m
2) was given on day 1, within
a 3-week cycle. The SOX regimen was very effective, with
a response rate of 50% and a median PFS of 6.4 months. The
most common toxicity of grade 3 or higher was
thrombocytopaenia, typically associated with oxaliplatin [27].
Since the DLT of S-1/LV regimen was mucositis such as
diarrhea and stomatitis, the combination with oxaliplatin, the
toxicity proﬁle of which does not overlap with that of S-1/LV,
may be more appropriate than irinotecan for the treatment
of metastatic disease requiring intensive chemotherapy. The
preliminary results of a phase I study evaluating the S-1/LV
regimen plus oxaliplatin have been reported. S-1/LV was given
for 1 week followed by 1 week of rest, and oxaliplatin was
given every 2 weeks (SOL regimen). The S-1/LV regimen was
administered at the standard dose in Japan; the recommended
dose of oxaliplatin was determined to be 85 mg/m
2. In that
phase I study, ﬁve (83%) of the six patients who received the
recommended dose of S-1, LV, and oxaliplatin had PRs. DLTs
(grade 3 diarrhea and grade 3 hypertension) occurred in one
of the six patients [28]. As for combinations of S-1 and
irinotecan, a phase III study is going on to compare survival
between the FOLFIRI regimen and S-1 plus irinotecan (IRIS
original article Annals of Oncology
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scheduled to be available in the near future.
Our results indicate that the S-1/LV regimen is a promising
treatment of mCRC. On the basis of these preliminary data,
further clinical trials of S-1/LV-based chemotherapy are going
on. After the completion of these trials, phase III studies are
promptly required to validate the clinical usefulness of S-1/LV-
based chemotherapy.
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